Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation. It is not yet known if neoadjuvant radiation therapy is a more effective therapy for high-risk prostate cancer.
PURPOSE: Two-stage randomized trial to compare the effectiveness and safety of neoadjuvant radiotherapy and hormone therapy followed by radical prostatectomy in men with high-risk locally advanced prostate cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
PRIMARY OBJECTIVE:
- Success rate of salvage radiation therapy (SRT) measured as pathologic complete response (pCR) or pathologic near complete response (minimal residual disease, MRD) rate.
SECONDARY OBJECTIVES:
- PSA decline rate after neoadjuvant treatment, rate of undetectable PSA after RP, rate of positive surgical margin, and rate of pathologic down-staging (≤ ypT2N0) II. Biochemical recurrence-free survival rate (from date of randomization). III. Metastasis free survival.
- Prostate Cancer Death. V. Overall Survival
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants receive neoadjuvant hormone and radiation therapy, and then radical prostatectomy
ARM II: Participants receive neoadjuvant hormone therapy, and then radical prostatectomy.
After intervention, participants are followed up periodically for up to 20 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Neoadjuvant RT and ADT Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5). Gosereline 3.6mg sc injection at week 1, week 5, and week 9 |
Radiation: radiation therapy
Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
Drug: Goserelin 3.6 MG
Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Other Names:
Procedure: radical prostatectomy
Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
|
| Active Comparator: Neoadjuvant ADT Gosereline 3.6mg sc injection at week 1, week 5, and week 9 |
Drug: Goserelin 3.6 MG
Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Other Names:
Procedure: radical prostatectomy
Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
|
Outcome Measures
Primary Outcome Measures
- Pathologic outcome [From date of randomization to the date of radical prostatectomy, up to 100 weeks]
pathologic complete response (pCR) or pathologic near complete response (minimal residual disease, MRD) rate
Secondary Outcome Measures
- PSA decline percentage [From date of randomization to 10 years]
PSA decline is defined as nadir PSA value/baseline PSA value × 100
- PSA complete response rate [From date of randomization to 10 years]
Complete response is defined as a drop in PSA on protocol treatment to less than 0.2 ng/ml.
- PSA Recurrence [From date of randomization to 10 years]
Biochemical recurrence is defined as a rise in PSA to 0.2 ng/mL and a confirmatory value of 0.2 ng/mL or greater following radical prostatectomy
- Distant Failure [From date of randomization to 10 years]
Distant failure rate is estimated by the cumulative incidence method, with failure defined as the first occurrence of distant failure.
- Prostate Cancer Death [From date of randomization to 10 years]
Prostate cancer death rate us estimated by the cumulative incidence method, with failure defined as death due to prostate cancer or complications of trial.
- Overall Survival [From date of randomization to 10 years]
Overall survival is estimated by the Kaplan-Meier method, with failure defined as death by any cause.
- Progression-free Survival [From date of randomization to 10 years]
Progress-free survival is estimated by the Kaplan-Meier method, with failure defined as the first occurrence of PSA failure, local, regional or distant failure, or death from any cause.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Men with age from 20 to 75 years old
-
Signed an informed consent form (ICF) indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study; subjects must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
-
Histologically confirmed adenocarcinoma of the prostate
-
High-risk locally advanced disease defined by ≥1 of the following 3 criteria:
-
T3a-3b by DRE or MRI
-
Gleason score ≥ 8 (= Grade group 4)
-
PSA ≥20 ng/ml
-
Willing to undergo prostatectomy as primary treatment
-
ECOG Performance status 0 or 1
Exclusion Criteria:
-
Pathological finding of small cell, ductal or neuroendocrine carcinoma
-
Current or prior hormone therapy, radiotherapy, or chemotherapy
-
Evidence of metastasis (M1) on images
-
Other prior malignancy ≤5 years prior to enrollment
-
Any of the following within 6 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated deep vein thrombosis is not considered exclusionary
-
Human immunodeficiency virus-positive subjects with 1 or more of the following:
-
Not receiving highly active antiretroviral therapy
-
Had a change in antiretroviral therapy within 6 months of the start of screening
-
Receiving antiretroviral therapy that may interfere with study drug (consult sponsor for review of medication prior to enrollment)
-
CD4 count <350 at screening
-
AIDS-defining opportunistic infection within 6 months of start of screening
-
Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding disorders secondary to hepatic dysfunction
-
History of seizure or any condition that may predispose to seizure (including, but not limited to, prior stroke, transient ischemic attack, or loss of consciousness ≤1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
-
Gastrointestinal conditions affecting absorption
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Taiwan University Hospital Yunlin Branch | Douliu City/Huwei Township | Yunlin County | Taiwan | |
| 2 | National Taiwan University Hospital | Tapiei | Taiwan |
Sponsors and Collaborators
- National Taiwan University Hospital
Investigators
- Principal Investigator: Chao-Yuan Huang, MD, PhD, National Taiwan University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 202101088RINA